RBFC
UTHR icon

Roman Butler Fullerton & Co’s United Therapeutics UTHR Stock Holding History

Roman Butler Fullerton & Co’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,551
Closed -$1.57M – 180
2022
Q2 		$1.57M Buy
+6,551
New +$1.33M 0.87% 27

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Roman Butler Fullerton & Co's UTHR Position: Q3 2022 in Review

Roman Butler Fullerton & Co sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 6,551 shares — an estimated $1.57M sold.

Roman Butler Fullerton & Co first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $1.57M in Q2 2022. 459 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Roman Butler Fullerton & Co reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 6,551 United Therapeutics shares in Q3 2022, an estimated $1.57M.
  • Roman Butler Fullerton & Co first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
  • Roman Butler Fullerton & Co's United Therapeutics position peaked at $1.57M in Q2 2022.
  • 459 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Roman Butler Fullerton & Co's 13F filing for Q3 2022, filed 17 Oct 2022.